Pharmacology, Toxicology and Pharmaceutical Science
Multi-Drug-Resistant Tuberculosis
100%
Pharmacokinetics
56%
Therapeutic Drug Monitoring
41%
Mycobacterium Tuberculosis
34%
Linezolid
27%
Rifampicin
20%
Extensively Drug-Resistant Tuberculosis
19%
Ertapenem
18%
Cotrimoxazole
15%
Amikacin
14%
Pharmacodynamics
13%
Clarithromycin
13%
Pharmacokinetic Modeling
13%
Kanamycin
12%
Bedaquiline
12%
Disease
12%
Lung Tuberculosis
12%
Drug Resistant Tuberculosis
12%
Tuberculostatic Agent
10%
Carbapenem Derivative
10%
Antiinfective Agent
9%
Sulfamethoxazole
9%
Isoniazid
8%
Moxifloxacin
8%
Prevalence
8%
Mixed Infection
8%
Infection
7%
Levofloxacin
7%
Pharmacokinetic Parameter
7%
Elimination
6%
Adverse Drug Reaction
6%
Quinolone Derivative
6%
HIV
6%
Normal Human
6%
Hospital Infection
6%
Inflammation
6%
Carbapenemase Producing Enterobacteriaceae
6%
Pharmacotherapy
6%
Capreomycin
6%
Macrolide
6%
Enterobacteriaceae
6%
Paradoxical Reaction
6%
Microorganism
6%
Gamma Interferon
6%
Carbapenem
5%
Keyphrases
Tuberculosis
24%
Multidrug-resistant Tuberculosis (MDR-TB)
22%
Tuberculosis Patients
12%
Pharmacokinetic Modeling
12%
Netherlands
12%
Restricted Sampling
12%
Therapeutic Drug Monitoring
12%
Bedaquiline
12%
Population Pharmacokinetic Model
10%
Carbapenems
10%
Tuberculosis Treatment
8%
Rifampin
7%
Rifampicin-resistant Tuberculosis
7%
Linezolid
7%
Drug-resistant Mycobacterium Tuberculosis
6%
Ertapenem
6%
Medicine Availability
6%
Neurological Outcome
6%
Tuberculose
6%
Medicine Costs
6%
Extensively Drug-resistant
6%
Multidrug-resistant Mycobacterium Tuberculosis
6%
Optimal Sample Size
6%
HIV-TB
6%
Tuberculosis Elimination
6%
Assessment Method
6%
Level of Independence
6%
Neurological Recovery
6%
Healthy Volunteers
6%
Diagnosis Treatment
6%
Kanamycin
6%
Patients with Spinal Cord Injury
6%
Amikacin
6%
Europe
6%
Malnutrition
6%
Spinal Cord Injury
6%
Adult Patients
6%
Tumor
6%
Functional Recovery
6%
Malnutrition Assessment
6%
Multidrug
6%
Successful Treatment Outcome
6%
Dried Blood Spot Analysis
6%
Capreomycin
6%
Multidrug-resistant Enterobacteriaceae
6%
Functional Outcome
6%
Sore Throat
6%
Extensively Drug-resistant Tuberculosis
5%
Medicine and Dentistry
Multidrug Resistant Tuberculosis
43%
Tuberculosis Treatment
21%
Prevalence
17%
Health Care Cost
14%
Public Health
13%
Lung Tuberculosis
12%
Carbapenemase Producing Enterobacteriaceae
12%
Extensively Drug Resistant Tuberculosis
12%
Diagnosis
9%
Human Immunodeficiency Virus
9%
Mycobacterium Tuberculosis
8%
Patient-Data
8%
Patient Compliance
7%
Infection
6%
Bedaquiline
6%
Hospital Infection
6%
Adverse Drug Reaction
6%
Therapeutic Drug Monitoring
6%
Meta-Analysis
6%
Corticosteroid Therapy
6%
Odds Ratio
6%
Serositis
6%
Lung Lavage
6%
Carbapenem Derivative
6%
Drug Resistant Tuberculosis
6%
Neoplasm
6%
Health System
6%
Ethnic Group
6%
Epileptic Absence
6%
Ethnic Disparity
6%
Social Health
6%
Enterobacteriaceae
6%
Medicine
6%
Sore Throat
6%
Tuberculostatic Agent
5%
Drug Sensitivity
5%
